LOS ANGELES, CA--(Marketwired - May 12, 2015) - Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip™ 50, the FDA-cleared Green Alternative Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan OneTouch Ultra family of glucose testing meters, the most popular meter worldwide for diabetic use, announced today that it has applied for a listing for its securities to trade on OTCQX, a higher tier of the Over The Counter (OTC) markets, overseen by OTCMarkets, Inc.
OTCQX is a segment of the OTC marketplace reserved for publicly traded companies that have attained specific quantitative and qualitative financial standards, pass management reviews, issue timely information to the public, are current on required disclosure, and consistently share pertinent updates with investors. OTCQX companies are more widely quoted across the electronic and retail brokerage markets.
Keith Berman, Principal Executive and CFO of Decision Diagnostics stated, "The Company has expended considerable resources to meet all financial reporting obligations required by OTCMarkets, Inc., and have now completed the submission of all pending financial applications. Pursuant to OTCQX rules, the company is also sponsored by a third-party Designated Advisor for Disclosure (DAD). Approved DADs serve as a securities professional knowledgeable in both the disclosure requirements of U.S. securities laws and the most effective investor communications practices. We are now fully current with our reporting and are anxious to forge forward. Filing an application to uplist for trading on OTCQX is the next step of financial reporting progression and the wider quoting of our securities."
Stocks of approximately 10,000 companies are traded daily in the multi-tier OTC Markets, yet only the top tier qualify to trade on the OTCQX. Those companies are characterized by operational excellence and consistent reporting diligence. Decision Diagnostics is certainly a company within that echelon. We expect that our application will be shortly reviewed and quickly approved.
Mr. Berman concluded, "At the close of the review of our OTCQX application, DECN will host a conference call to inform our shareholders and others in the investment community of the company's progress and our plans for the near future. The summer portends an exciting period of growth, promise and success for the company."
This release contains forward-looking statements about our business or financial condition that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this release, words such as "believes," "expects," "forecasts," "intends," "projects," "plans," "anticipates," "estimates," "will" and similar expressions are intended to identify forward-looking statements, although there may be certain statements not accompanied by such expressions.
For further information about the Pharma Tech GenStrip™ 50, please visit the company's Web Sites: http://www.decisiondiagnostics.com or http://www.pharmatechdirect.com or http://www.new-genstrip.com.
GenStrip™ 50 test strips are a product of Pharma Tech Solutions, Inc., and are not manufactured, distributed, endorsed, or approved by nor associated with LifeScan, Inc. a Johnson & Johnson company, manufacturers and distributors of the OneTouch Ultra family of meters and OneTouch Ultra test strips.